Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,44,440 Cr
Revenue (TTM)
₹12,742 Cr
Net Profit (TTM)
₹2,272 Cr
ROE
26.5 %
ROCE
27.3 %
P/E Ratio
63.6
P/B Ratio
15.9
Industry P/E
27.85
EV/EBITDA
35.9
Div. Yield
0.7 %
Debt to Equity
0.4
Book Value
₹268.4
EPS
₹68.2
Face value
5
Shares outstanding
338,445,440
CFO
₹19,863.76 Cr
EBITDA
₹24,398.23 Cr
Net Profit
₹11,647.94 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Torrent Pharma
| 10.9 | 1.0 | 12.4 | 33.8 | 40.7 | 28.7 | 20.6 |
|
BSE Sensex
| -12.0 | -9.7 | -12.2 | -1.2 | 8.7 | 8.4 | 11.6 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Torrent Pharma
| 12.6 | 46.3 | 48.7 | -5.4 | 17.3 | 52.0 | 4.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Torrent Pharma
|
4,270.2 | 1,44,440.1 | 12,742.0 | 2,272.0 | 26.3 | 28.8 | 63.6 | 15.9 |
| 5,257.5 | 62,864.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 26.5 | 4.5 | |
| 1,291.4 | 75,004.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.5 | 2.1 | |
| 381.0 | 61,740.4 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.2 | 1.6 | |
| 1,256.4 | 1,01,445.4 | 28,351.1 | 4,544.7 | 18.8 | 14.8 | 22.3 | 3.0 | |
| 1,298.9 | 1,08,417.3 | 34,682.2 | 5,508.7 | 17.6 | 16 | 19.5 | 2.9 | |
| 2,322.5 | 1,06,146.0 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.9 | 5.1 | |
| 2,000.0 | 82,555.3 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 46.4 | 5.3 | |
| 1,777.1 | 4,26,469.8 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 890.5 | 89,615.2 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.1 | 3.4 |
2 min read•By Mohammed Ekramul Haque
Which stocks are vulnerable to Brexit?
4 min read•By Kumar Shankar Roy
3 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
2 min read•By Vikas Vardhan
4 min read•By Saurabh Mukherjea
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers... products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited. Read more
Incorporated
1972
Chairman
Samir Mehta
Managing Director
Aman Mehta
Group
Torrent
Headquarters
Ahmedabad, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Torrent Pharmaceuticals Ltd is ₹4,270.20 (NSE) and ₹4,267.75 (BSE) as of 20-Mar-2026 IST. Torrent Pharmaceuticals Ltd has given a return of 40.67% in the last 3 years.
The P/E ratio of Torrent Pharmaceuticals Ltd is 63.57 times as on 20-Mar-2026, a 128 premium to its peers’ median range of 27.85 times.
The P/B ratio of Torrent Pharmaceuticals Ltd is 15.90 times as on 20-Mar-2026, a 254 premium to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
57.28
|
14.42
|
|
2024
|
53.15
|
12.84
|
|
2023
|
41.79
|
8.40
|
|
2022
|
30.45
|
7.95
|
|
2021
|
17.18
|
7.37
|
The 52-week high and low of Torrent Pharmaceuticals Ltd are Rs 4,482.90 and Rs 3,101.60 as of 22-Mar-2026.
Torrent Pharmaceuticals Ltd has a market capitalisation of ₹ 1,44,440 Cr as on 20-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Torrent Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹59.40
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.